JP7307733B2 - キナーゼ依存的障害を処置するための化合物 - Google Patents

キナーゼ依存的障害を処置するための化合物 Download PDF

Info

Publication number
JP7307733B2
JP7307733B2 JP2020540750A JP2020540750A JP7307733B2 JP 7307733 B2 JP7307733 B2 JP 7307733B2 JP 2020540750 A JP2020540750 A JP 2020540750A JP 2020540750 A JP2020540750 A JP 2020540750A JP 7307733 B2 JP7307733 B2 JP 7307733B2
Authority
JP
Japan
Prior art keywords
alkyl
alkylene
cycloalkyl
membered heterocycloalkyl
membered heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020540750A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019148036A5 (enExample
JP2021511359A (ja
Inventor
リン カンヌ バネン，
ミンナ ブイ，
ファミン ジャン，
ヨン ワン，
ウェイ シュー，
Original Assignee
エグゼリクシス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エグゼリクシス， インコーポレイテッド filed Critical エグゼリクシス， インコーポレイテッド
Publication of JP2021511359A publication Critical patent/JP2021511359A/ja
Publication of JPWO2019148036A5 publication Critical patent/JPWO2019148036A5/ja
Priority to JP2023045583A priority Critical patent/JP7596427B2/ja
Application granted granted Critical
Publication of JP7307733B2 publication Critical patent/JP7307733B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2020540750A 2018-01-26 2019-01-25 キナーゼ依存的障害を処置するための化合物 Active JP7307733B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023045583A JP7596427B2 (ja) 2018-01-26 2023-03-22 キナーゼ依存的障害を処置するための化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862622629P 2018-01-26 2018-01-26
US201862622626P 2018-01-26 2018-01-26
US62/622,626 2018-01-26
US62/622,629 2018-01-26
PCT/US2019/015289 WO2019148036A1 (en) 2018-01-26 2019-01-25 Compounds for the treatment of kinase-dependent disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023045583A Division JP7596427B2 (ja) 2018-01-26 2023-03-22 キナーゼ依存的障害を処置するための化合物

Publications (3)

Publication Number Publication Date
JP2021511359A JP2021511359A (ja) 2021-05-06
JPWO2019148036A5 JPWO2019148036A5 (enExample) 2022-02-24
JP7307733B2 true JP7307733B2 (ja) 2023-07-12

Family

ID=65409542

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020540750A Active JP7307733B2 (ja) 2018-01-26 2019-01-25 キナーゼ依存的障害を処置するための化合物
JP2023045583A Active JP7596427B2 (ja) 2018-01-26 2023-03-22 キナーゼ依存的障害を処置するための化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023045583A Active JP7596427B2 (ja) 2018-01-26 2023-03-22 キナーゼ依存的障害を処置するための化合物

Country Status (20)

Country Link
US (2) US11708367B2 (enExample)
EP (1) EP3743068A1 (enExample)
JP (2) JP7307733B2 (enExample)
KR (1) KR102759973B1 (enExample)
CN (1) CN112312909B (enExample)
AU (1) AU2019212719B2 (enExample)
BR (1) BR112020015199A2 (enExample)
CA (1) CA3088127A1 (enExample)
CL (1) CL2020001930A1 (enExample)
CO (1) CO2020010467A2 (enExample)
CR (2) CR20200355A (enExample)
IL (2) IL276028B2 (enExample)
MA (1) MA51672A (enExample)
MX (2) MX2020007759A (enExample)
PE (1) PE20210044A1 (enExample)
PH (1) PH12020551059A1 (enExample)
SA (1) SA520412488B1 (enExample)
SG (1) SG11202006945PA (enExample)
UA (1) UA128348C2 (enExample)
WO (1) WO2019148036A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019148036A1 (en) * 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
EP3743417A1 (en) 2018-01-26 2020-12-02 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
SG11202006921PA (en) * 2018-01-26 2020-08-28 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
CN112457308B (zh) 2019-09-09 2024-01-02 上海长森药业有限公司 新型三环芳香杂环化合物，及其制备方法、药物组合物和应用
CN115244041A (zh) * 2020-03-10 2022-10-25 南京明德新药研发有限公司 乙烯基取代吡啶类化合物
GB202004960D0 (en) * 2020-04-03 2020-05-20 Kinsenus Ltd Inhibitor compounds
US12497367B2 (en) 2020-04-30 2025-12-16 Exelixis, Inc. Processes for the preparation of a kinase inhibitor
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations
CN117164527A (zh) * 2022-05-25 2023-12-05 大连理工大学 一种钒催化杂环芳香腈水解制备杂环芳香酰胺的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007506777A (ja) 2003-09-26 2007-03-22 エグゼリクシス， インコーポレイテッド ｃ−Ｍｅｔモジュレーターおよびその使用
JP2012505888A (ja) 2008-10-14 2012-03-08 クイ ニング 化合物及び使用方法
JP2013531016A (ja) 2010-07-14 2013-08-01 ジャージャン ベータ ファーマ インコーポレイテッド ｃ−ＭＥＴチロシンキナーゼ阻害薬として有用な新規な縮合複素環式誘導体
JP2013537197A (ja) 2010-09-12 2013-09-30 アドヴェンチェン ラボラトリーズ，エルエルシー ｃ−Ｍｅｔキナーゼ阻害剤としての化合物
JP2018520109A (ja) 2015-05-21 2018-07-26 中国科学院上海薬物研究所Ｓｈａｎｇｈａｉ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍａｔｅｒｉａ Ｍｅｄｉｃａ， Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ Ｏｆ Ｓｃｉｅｎｃｅｓ ピリド−アザヘテロサイクリック化合物及びその製造方法と用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
WO1996030347A1 (en) 1995-03-30 1996-10-03 Pfizer Inc. Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
ATE213730T1 (de) 1996-04-12 2002-03-15 Warner Lambert Co Umkehrbare inhibitoren von tyrosin kinasen
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
JP4679517B2 (ja) 2003-07-23 2011-04-27 エグゼリクシス， インコーポレイテッド 薬剤としてのアゼピン誘導体
EP1871417B1 (en) 2005-04-15 2013-09-11 Precision Biologics, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
EP1896582A4 (en) 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
RU2008139599A (ru) 2006-03-07 2010-04-20 Эррэй Биофарма Инк. (Us) Гетеробициклические производные пиразола и способы их применения
EP2213686A1 (en) 2009-01-28 2010-08-04 Externautics S.p.A. Tumor markers and methods of use thereof
EP2214019A1 (en) 2009-01-28 2010-08-04 Externautics S.p.A. Tumor markers and methods of use thereof
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP3345920A1 (en) 2009-10-26 2018-07-11 Externautics S.p.A. Breast tumor markers and methods of use thereof
WO2011051271A2 (en) 2009-10-26 2011-05-05 Externautics S.P.A. Prostate tumor markers and methods of use thereof
WO2011051278A1 (en) 2009-10-26 2011-05-05 Externautics S.P.A. Lung tumor markers and methods of use thereof
WO2011051276A1 (en) 2009-10-26 2011-05-05 Externautics S.P.A. Colon and rectal tumor markers and methods of use thereof
EP2494361B2 (en) 2009-10-26 2019-01-09 Externautics S.p.A. Ovary tumor markers and methods of use thereof
EP2383578A1 (en) 2010-04-30 2011-11-02 Externautics S.p.A. Tumor marker and methods of use thereof
CN102093421B (zh) 2011-01-28 2014-07-02 北京康辰药业有限公司 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
CN102408411B (zh) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
CN104994873B (zh) 2012-10-04 2017-12-22 达纳－法伯癌症研究所公司 人单克隆抗‑pd‑l1抗体和使用方法
ES2845609T3 (es) 2013-05-02 2021-07-27 Anaptysbio Inc Anticuerpos dirigidos contra muerte programada-1 (PD-1)
WO2014198919A2 (en) 2013-06-14 2014-12-18 Externautics S.P.A. Tumor marker, monoclonal antibodies and methods of use thereof
EP3065772B1 (en) 2013-11-05 2024-07-24 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
CA2946416C (en) 2014-04-25 2022-07-19 Exelixis, Inc. Method of treating lung adenocarcinoma
CN104817497B (zh) 2015-03-20 2017-03-08 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途
US20180009758A1 (en) 2015-06-29 2018-01-11 Ontogenesis, Llc Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
CN105797123A (zh) 2016-05-18 2016-07-27 王超 一种治疗不孕不育的中药组合物
CN106400155A (zh) 2016-08-31 2017-02-15 飞佛特种纺织品（宁波）有限公司 一种防老化阳光面料
CN110437145A (zh) 2016-09-13 2019-11-12 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用
AU2018388439B2 (en) 2017-12-20 2021-05-20 Angex Pharmaceutical, Inc. Carbamate and urea compounds as multikinase inhibitors
WO2019148036A1 (en) * 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007506777A (ja) 2003-09-26 2007-03-22 エグゼリクシス， インコーポレイテッド ｃ−Ｍｅｔモジュレーターおよびその使用
JP2012505888A (ja) 2008-10-14 2012-03-08 クイ ニング 化合物及び使用方法
JP2013531016A (ja) 2010-07-14 2013-08-01 ジャージャン ベータ ファーマ インコーポレイテッド ｃ−ＭＥＴチロシンキナーゼ阻害薬として有用な新規な縮合複素環式誘導体
JP2013537197A (ja) 2010-09-12 2013-09-30 アドヴェンチェン ラボラトリーズ，エルエルシー ｃ−Ｍｅｔキナーゼ阻害剤としての化合物
JP2018520109A (ja) 2015-05-21 2018-07-26 中国科学院上海薬物研究所Ｓｈａｎｇｈａｉ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍａｔｅｒｉａ Ｍｅｄｉｃａ， Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ Ｏｆ Ｓｃｉｅｎｃｅｓ ピリド−アザヘテロサイクリック化合物及びその製造方法と用途

Also Published As

Publication number Publication date
CA3088127A1 (en) 2019-08-01
MX2020007759A (es) 2020-09-24
CL2020001930A1 (es) 2020-12-11
CN112312909B (zh) 2024-07-02
US20210040099A1 (en) 2021-02-11
AU2019212719B2 (en) 2024-12-05
SA520412488B1 (ar) 2024-06-23
US20230374024A1 (en) 2023-11-23
IL276028B2 (en) 2025-02-01
IL302626A (en) 2023-07-01
BR112020015199A2 (pt) 2021-05-04
IL302626B2 (en) 2025-12-01
UA128348C2 (uk) 2024-06-19
MX2022014351A (es) 2022-12-13
KR20200124678A (ko) 2020-11-03
JP2023082042A (ja) 2023-06-13
PE20210044A1 (es) 2021-01-08
IL276028B1 (en) 2024-10-01
MA51672A (fr) 2020-12-02
KR102759973B1 (ko) 2025-01-23
CN112312909A (zh) 2021-02-02
AU2019212719A1 (en) 2020-08-20
IL276028A (en) 2020-08-31
CR20250117A (es) 2025-05-09
EP3743068A1 (en) 2020-12-02
JP7596427B2 (ja) 2024-12-09
WO2019148036A1 (en) 2019-08-01
US11708367B2 (en) 2023-07-25
JP2021511359A (ja) 2021-05-06
CO2020010467A2 (es) 2020-10-30
PH12020551059A1 (en) 2021-05-31
SG11202006945PA (en) 2020-08-28
CR20200355A (es) 2021-02-22
IL302626B1 (en) 2025-08-01
US12195475B2 (en) 2025-01-14

Similar Documents

Publication Publication Date Title
JP7690517B2 (ja) キナーゼ依存的障害を処置するための化合物
JP7596427B2 (ja) キナーゼ依存的障害を処置するための化合物
US20240150371A1 (en) Compounds for the Treatment of Kinase-Dependent Disorders
HK40046174B (zh) 用於治疗激酶依赖性病症的化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221221

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230322

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230602

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230630

R150 Certificate of patent or registration of utility model

Ref document number: 7307733

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150